Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11.

2.

BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.

Biswas K, Philip S, Yadav A, Martin BK, Burkett S, Singh V, Babbar A, North SL, Chang S, Sharan SK.

Nat Commun. 2018 Feb 7;9(1):537. doi: 10.1038/s41467-018-03020-6.

3.

Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative.

Johnsen JM, Fletcher SN, Huston H, Roberge S, Martin BK, Kircher M, Josephson NC, Shendure J, Ruuska S, Koerper MA, Morales J, Pierce GF, Aschman DJ, Konkle BA.

Blood Adv. 2017 May 18;1(13):824-834. doi: 10.1182/bloodadvances.2016002923. eCollection 2017 May 23.

4.

Survival of BRCA2-Deficient Cells Is Promoted by GIPC3, a Novel Genetic Interactor of BRCA2.

Ding X, Philip S, Martin BK, Pang Y, Burkett S, Swing DA, Pamala C, Ritt DA, Zhou M, Morrison DK, Ji X, Sharan SK.

Genetics. 2017 Dec;207(4):1335-1345. doi: 10.1534/genetics.117.300357. Epub 2017 Oct 11.

5.

Caspase-8, association with Alzheimer's Disease and functional analysis of rare variants.

Rehker J, Rodhe J, Nesbitt RR, Boyle EA, Martin BK, Lord J, Karaca I, Naj A, Jessen F, Helisalmi S, Soininen H, Hiltunen M, Ramirez A, Scherer M, Farrer LA, Haines JL, Pericak-Vance MA, Raskind WH, Cruchaga C, Schellenberg GD, Joseph B, Brkanac Z.

PLoS One. 2017 Oct 6;12(10):e0185777. doi: 10.1371/journal.pone.0185777. eCollection 2017.

6.

Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses.

Chen WA, Zhang J, Hall KM, Martin CB, Kisselev S, Dasen EJ, Vahanian NN, Link CJ, Martin BK.

PLoS One. 2017 Aug 7;12(8):e0182683. doi: 10.1371/journal.pone.0182683. eCollection 2017.

7.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.

Heppner DG Jr, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA, Monath TP; V920-004 study team.

Lancet Infect Dis. 2017 Aug;17(8):854-866. doi: 10.1016/S1473-3099(17)30313-4. Epub 2017 Jun 9.

PMID:
28606591
8.

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.

Ding X, Ray Chaudhuri A, Callen E, Pang Y, Biswas K, Klarmann KD, Martin BK, Burkett S, Cleveland L, Stauffer S, Sullivan T, Dewan A, Marks H, Tubbs AT, Wong N, Buehler E, Akagi K, Martin SE, Keller JR, Nussenzweig A, Sharan SK.

Nat Commun. 2016 Aug 8;7:12425. doi: 10.1038/ncomms12425.

9.

BRCA2 minor transcript lacking exons 4-7 supports viability in mice and may account for survival of humans with a pathogenic biallelic mutation.

Thirthagiri E, Klarmann KD, Shukla AK, Southon E, Biswas K, Martin BK, North SL, Magidson V, Burkett S, Haines DC, Noer K, Matthai R, Tessarollo L, Loncarek J, Keller JR, Sharan SK.

Hum Mol Genet. 2016 May 15;25(10):1934-1945. Epub 2016 Feb 26.

10.

Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-β-mediated MDSC infiltration.

Kim S, Song JH, Kim S, Qu P, Martin BK, Sehareen WS, Haines DC, Lin PC, Sharan SK, Chang S.

Oncotarget. 2016 Mar 8;7(10):11094-112. doi: 10.18632/oncotarget.7150.

11.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

12.

MIPgen: optimized modeling and design of molecular inversion probes for targeted resequencing.

Boyle EA, O'Roak BJ, Martin BK, Kumar A, Shendure J.

Bioinformatics. 2014 Sep 15;30(18):2670-2. doi: 10.1093/bioinformatics/btu353. Epub 2014 May 26.

13.

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2.

Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; DIADS-2 Research Group.

Am J Geriatr Psychiatry. 2014 Jan;22(1):14-24. doi: 10.1016/j.jagp.2013.02.014.

14.

The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line.

Adey A, Burton JN, Kitzman JO, Hiatt JB, Lewis AP, Martin BK, Qiu R, Lee C, Shendure J.

Nature. 2013 Aug 8;500(7461):207-11. doi: 10.1038/nature12064.

15.

Experience Corps: a dual trial to promote the health of older adults and children's academic success.

Fried LP, Carlson MC, McGill S, Seeman T, Xue QL, Frick K, Tan E, Tanner EK, Barron J, Frangakis C, Piferi R, Martinez I, Gruenewald T, Martin BK, Berry-Vaughn L, Stewart J, Dickersin K, Willging PR, Rebok GW.

Contemp Clin Trials. 2013 Sep;36(1):1-13. doi: 10.1016/j.cct.2013.05.003. Epub 2013 May 13.

16.

Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.

O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, Carvill G, Kumar A, Lee C, Ankenman K, Munson J, Hiatt JB, Turner EH, Levy R, O'Day DR, Krumm N, Coe BP, Martin BK, Borenstein E, Nickerson DA, Mefford HC, Doherty D, Akey JM, Bernier R, Eichler EE, Shendure J.

Science. 2012 Dec 21;338(6114):1619-22. doi: 10.1126/science.1227764. Epub 2012 Nov 15.

17.

Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.

Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; Depression in Alzheimer’s Disease Study–2 Research Group.

Am J Geriatr Psychiatry. 2012 Dec;20(12):1036-44. doi: 10.1097/JGP.0b013e31826ce4c5.

18.

Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.

Biswas K, Das R, Eggington JM, Qiao H, North SL, Stauffer S, Burkett SS, Martin BK, Southon E, Sizemore SC, Pruss D, Bowles KR, Roa BB, Hunter N, Tessarollo L, Wenstrup RJ, Byrd RA, Sharan SK.

Hum Mol Genet. 2012 Sep 15;21(18):3993-4006. doi: 10.1093/hmg/dds222. Epub 2012 Jun 7.

19.

Sertraline for the treatment of depression in Alzheimer disease: genetic influences.

Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J, Weintraub D, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Avramopoulos D; DIADS-2 Research Group.

J Geriatr Psychiatry Neurol. 2011 Dec;24(4):222-8. doi: 10.1177/0891988711422527. Erratum in: J Geriatr Psychiatry Neurol. 2012 Sep;25(3):188. Dimitri, Avramopoulos [corrected to Avramopoulos, Dimitri].

20.

Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.

Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK.

Nat Med. 2011 Sep 25;17(10):1275-82. doi: 10.1038/nm.2459. Erratum in: Nat Med. 2011 Nov;17(11):1521. Nat Med. 2011 Oct;17(10):2 p following 1282.

21.

c-Jun and c-Fos regulate the complement factor H promoter in murine astrocytes.

Fraczek LA, Martin CB, Martin BK.

Mol Immunol. 2011 Oct;49(1-2):201-10. doi: 10.1016/j.molimm.2011.08.013. Epub 2011 Sep 14.

22.

Extended results of the Alzheimer's disease anti-inflammatory prevention trial.

Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN; ADAPT Research Group.

Alzheimers Dement. 2011 Jul;7(4):402-11. doi: 10.1016/j.jalz.2010.12.014.

23.

Transcriptional control of genes for soluble complement cascade regulatory proteins.

Fraczek LA, Martin BK.

Mol Immunol. 2010 Nov-Dec;48(1-3):9-13. doi: 10.1016/j.molimm.2010.08.016. Epub 2010 Sep 25. Review.

PMID:
20869772
24.

CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model.

Ingersoll SA, Martin CB, Barnum SR, Martin BK.

Mol Immunol. 2010 Nov-Dec;48(1-3):219-30. doi: 10.1016/j.molimm.2010.08.007. Epub 2010 Sep 1.

25.

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?

Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; DIADS-2 Research Group.

Int J Geriatr Psychiatry. 2011 Jun;26(6):573-83. doi: 10.1002/gps.2565.

26.

Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles.

Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Holbrook MR, Martin BK, Vahanian N, Link CJ, Flick R.

J Virol Methods. 2010 Nov;169(2):259-68. doi: 10.1016/j.jviromet.2010.07.015. Epub 2010 Jul 22.

PMID:
20655330
27.

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group.

Am J Geriatr Psychiatry. 2010 Apr;18(4):332-40. doi: 10.1097/JGP.0b013e3181cc0333.

28.

Sertraline for the treatment of depression in Alzheimer disease.

Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group.

Am J Geriatr Psychiatry. 2010 Feb;18(2):136-45. doi: 10.1097/JGP.0b013e3181c796eb.

29.

A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, Holbrook MR, Martin BK, Staplin WR, Vahanian NN, Link CJ, Flick R.

Virology. 2010 Feb 5;397(1):187-98. doi: 10.1016/j.virol.2009.11.001. Epub 2009 Nov 24.

30.

Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.

Jabs DA, Martin BK, Forman MS; Cytomegalovirus Retinitis and Viral Resistance Research Group.

Ophthalmology. 2010 Jan;117(1):128-132.e2. doi: 10.1016/j.ophtha.2009.06.016. Epub 2009 Oct 8.

31.

Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.

Chang S, Biswas K, Martin BK, Stauffer S, Sharan SK.

J Clin Invest. 2009 Oct;119(10):3160-71. doi: 10.1172/JCI39836. Epub 2009 Sep 21.

32.

Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice.

Kuznetsov SG, Haines DC, Martin BK, Sharan SK.

Cancer Res. 2009 Feb 1;69(3):863-72. doi: 10.1158/0008-5472.CAN-08-3057. Epub 2009 Jan 20.

33.

Do we need to adjudicate major clinical events?

Meinert CL, Martin BK, McCaffrey LD, Breitner JC.

Clin Trials. 2008;5(5):557; author reply 558. doi: 10.1177/1740774508096007. No abstract available.

PMID:
18827048
34.

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M.

Arch Neurol. 2008 Jul;65(7):896-905. doi: 10.1001/archneur.2008.65.7.nct70006. Epub 2008 May 12.

35.

Transcriptional control of complement receptor gene expression.

Martin BK.

Immunol Res. 2007;39(1-3):146-59. Review.

PMID:
17917062
36.
37.

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M.

Neurology. 2007 May 22;68(21):1800-8. Epub 2007 Apr 25.

PMID:
17460158
38.

The trialist, meta-analyst, and journal editor: lessons from ADAPT.

Martin BK, Breitner JC, Evans D, Lyketsos CG, Meinert CL.

Am J Med. 2007 Mar;120(3):192-3. No abstract available.

PMID:
17349436
39.

Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis.

Martin BK, Ricks MO, Forman MS, Jabs DA; Cytomegalovirus Retinitis and Viral Resistance Study Group.

Clin Infect Dis. 2007 Apr 1;44(7):1001-8. Epub 2007 Feb 20.

PMID:
17342657
40.

RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females.

Kuznetsov S, Pellegrini M, Shuda K, Fernandez-Capetillo O, Liu Y, Martin BK, Burkett S, Southon E, Pati D, Tessarollo L, West SC, Donovan PJ, Nussenzweig A, Sharan SK.

J Cell Biol. 2007 Feb 26;176(5):581-92. Epub 2007 Feb 20.

41.

The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen.

Breitner JC, Martin BK, Meinert CL.

PLoS Clin Trials. 2006 Dec 22;1(8):e41. No abstract available.

42.

Design of Depression in Alzheimer's Disease Study-2.

Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Niederehe G, Lyketsos CG.

Am J Geriatr Psychiatry. 2006 Nov;14(11):920-30.

PMID:
17068314
43.

Transcriptional control of the C3a receptor gene in glial cells: Dependence upon AP-1 but not Ets.

Martin CB, Ingersoll SA, Martin BK.

Mol Immunol. 2007 Feb;44(5):703-12. Epub 2006 Jul 18.

PMID:
16854466
44.

Regulation of the C5a receptor promoter in glial cells: Minimal dependence upon the CCAAT element in astrocytes.

Martin CB, Ingersoll SA, Martin BK.

Mol Immunol. 2007 Feb;44(5):713-21. Epub 2006 Jun 5.

PMID:
16750856
45.

Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome.

Jabs DA, Martin BK, Ricks MO, Forman MS; Cytomegalovirus Retinitis and Viral Resistance Study Group.

J Infect Dis. 2006 Jun 15;193(12):1728-37. Epub 2006 May 10.

PMID:
16703517
46.

A call for empirical research on best practices for economic evaluation in ophthalmic outcomes research.

Frick KD, Clark MA, Martin BK, Grover LL.

Ophthalmic Epidemiol. 2006 Apr;13(2):81-3. No abstract available.

PMID:
16581611
47.

Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration.

Martin BK, Wu AW, Gelman R, Mitsuyasu RT; Adult AIDS Clinical Trials Group.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):428-33.

PMID:
16280697
48.

The impact of anemia on energy and physical functioning in individuals with AIDS.

Semba RD, Martin BK, Kempen JH, Thorne JE, Wu AW; Ocular Complications of AIDS Research Group.

Arch Intern Med. 2005 Oct 24;165(19):2229-36.

PMID:
16246988
49.

Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis.

Reiman R, Campos Torres A, Martin BK, Ting JP, Campbell IL, Barnum SR.

Neurosci Lett. 2005 Dec 30;390(3):134-8. Epub 2005 Sep 9.

PMID:
16154690

Supplemental Content

Loading ...
Support Center